Cerecor Announces Acquisition of TARP-γ8-AMPA Receptor Antagonist (CERC611) from Lilly

Cerecor Inc. (CERC), a clinical stage biopharmaceutical company developing treatments to make a difference in the lives of patients with neurological and psychiatric disorders, today announced that it has acquired exclusive, worldwide rights from Eli Lilly and Company (“Lilly”) to develop and
commercialize LY3130418 (now designated as CERC611).

This entry was posted in Recent Development News: Q3 - 2016, Recent Developments. Bookmark the permalink.
Read Full Article »